Effective Adjunctive Use of Pergolide for Cognitive Impairment and Negative Symptoms in Schizophrenia
Status:
Suspended
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Dopamine has been closely associated with prefrontal function. The hypothesis that a lower
dopaminergic activity is associated with negative symptoms and cognitive dysfunction observed
in the patients of schizophrenia is of a heuristic value in guiding research in this area.
This hypothesis led us to test whether pergolide, a D1/D2 agonist, could improve negative
symptoms and cognitive impairments prevailing in most patients with schizophrenia. This
double-blind placebo controlled study will investigate the remedial effect of pergolide on
negative symptoms and cognitive impairments in schizophrenia.